WO1996024361A1 - Method for relieving or treating skin discomfort - Google Patents
Method for relieving or treating skin discomfort Download PDFInfo
- Publication number
- WO1996024361A1 WO1996024361A1 PCT/US1996/001669 US9601669W WO9624361A1 WO 1996024361 A1 WO1996024361 A1 WO 1996024361A1 US 9601669 W US9601669 W US 9601669W WO 9624361 A1 WO9624361 A1 WO 9624361A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyaluronic acid
- acid salt
- skin
- stump
- discomfort
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
Definitions
- NaHA Sodium hyaluronate
- NaHA is present in various connective tissues of animals, such as skin and cartilage. Some organs are specifically rich in HA, such as the umbilical cord, synovial fluid, the vitreous humor, and rooster combs. In addition, NaHA is produced by various microorganisms, such as Streptococci Type A and C.
- the role of NaHA is to bind water and retain the tonicity and elasticity of the tissue.
- the viscous NaHA solution serves as a lubricant to provide a protective environment to the cells.
- synovial fluid acts to lubricate effectively the surfaces of bones that are in frictional contact to form joints (3) .
- NaHA is used by means of interarticular injections, as adjuvant in the therapy of degenerative and/or inflammatory diseases of the articular synovial sheaths (2) .
- NaHA is widely used in ophthalmic surgery, due to its elasto-viscous properties and rheologic properties (1) .
- NaHA is used in cataract operations that are associated with intraocular lens implantation, as well as glaucoma and corneal transplant operations and more generally in any traumatopathy involving retinal detachment (2) .
- diluted solutions of NaHA less than 0.2%w/v, may be used to relieve symptoms of lacrimal film diseases (2) .
- the instant invention relates to a method of relieving and preventing discomfort experienced by an amputee upon wearing a prosthetic device on a stump of an amputated limb.
- the instant invention relates to method of relieving and preventing discomfort associated with chafing of skin.
- the subject invention provides a method of relieving and preventing discomfort experienced by an amputee upon wearing a prosthetic device on a stump of an amputated limb while permitting continued wearing by the amputee of the prosthetic device which comprises applying to the surface of the stump an amount of a hyaluronic acid salt effective to relieve such discomfort prior to placing the prosthetic device on the stump and then placing the prosthetic device on the stump without removing the hyaluronic acid salt.
- the subject invention further provides a method of relieving and preventing discomfort associated with chafing of skin which comprises applying to the surface of the chafed skin an amount of a hyaluronic acid salt effective to relieve such discomfort .
- hyaluronic acid salt encompasses hyaluronic acid or any of its salts.
- the sodium salt of hyaluronic acid is especially preferred but other salts are also envisaged, see e.g. coassigned U.S. Patent No. 4,784,991.
- the hyaluronic acid salt may be produced from any source including bacteria, cockscombs or umbilical cord and may be produced by any purification procedure known in the art.
- the preferred hyaluronic acid salt was produced essentially as described in coassigned U.S. Patent Nos . 4,780,414 and 4,784,990.
- NaHA may also be produced as described in U.S. Patent No. 4,141,973 (Balazs) or EPO Patent Publication No. 144019 (Brown et al. ) .
- the subject invention provides a method of relieving and preventing discomfort experienced by an amputee upon wearing a prosthetic device (artificial limb) on a stump of an amputated limb while permitting continued wearing by the amputee of the prosthetic device which comprises applying to the surface of the stump an amount of a hyaluronic acid salt effective to relieve such discomfort prior to placing the prosthetic device on the stump and then placing the prosthetic device on the stump without removing the hyaluronic acid salt.
- skin lesion encompasses skin redness or soreness, painful tissue, dermatologically irritated skin, blisters and open wounds.
- the skin lesion is a skin wound and the hyaluronic acid salt is sodium hyaluronate.
- hyaluronic acid salts may be used to treat skin lesions on the stump of an amputated limb.
- hyaluronic acid salts may be used prophylactically to prevent the formation of skin lesions on the stump of an amputated limb.
- the subject invention further provides a method of relieving and preventing discomfort associated with chafing of the skin which comprises applying to the surface of the chafed skin an amount of a hyaluronic acid salt effective to relieve such discomfort.
- the chafed skin comprises a chafed upper leg and the hyaluronic acid salt is sodium hyaluronate.
- the subject invention also provides a use of an effective amount of a hyaluronic acid salt in the preparation of a composition for relieving and preventing discomfort experienced by an amputee upon wearing a prosthetic device on a stump of an amputated limb while permitting continued wearing by the amputee of the prosthetic device which comprises applying to the surface of the stump an amount of the composition effective to relieve and prevent such discomfort prior to placing the prosthetic device on the stump, and then placing the prosthetic device on the stump without removing the composition.
- the subject invention additionally provides a use of an effective amount of a hyaluronic acid salt in the preparation of a composition for relieving and preventing discomfort associated with chafing of skin which comprises applying to the surface of the chafed skin an amount of the composition effective to relieve and prevent such discomfort.
- the hyaluronic acid salt may be chemically modified or cross-linked in any manner, see for example U.S. 4,957,744 or U.S. 4,713,448, as long as the product is effective in the claimed use and can be used to relieve discomfort.
- the hyaluronic acid salt solution of the subject invention may have a concentration of from 0.05% to 5 % and preferably from 0.1% to 2%.
- the most preferred concentration of the hyaluronic acid salt solution to be used is from 0.1% to 1%.
- the molecular weight of the hyaluronic acid salt to be utilized may be from 30,000 to 13 million daltons and preferably from 300,000 to 2,000,000 daltons.
- Hyaluronic acid salts of various molecular weights are well known in the art; see for example EP Patent Publication 197718.
- the most preferred hyaluronic acid salt has a molecular weight of from 500,000 to 1,500,000 daltons.
- the hyaluronic acid salt solution may be administered with or without preservatives; any suitable preservative known in the art may be used.
- the hyaluronic acid salt solution has a concentration of about 0.5%, a molecular weight of between 700,000 to 1,500,000 daltons and comprises Germall and Phenonip preservatives.
- the subject invention further provides an article of manufacture comprising packaging material and a hyaluronic acid salt contained within said packaging material, wherein said hyaluronic acid salt is present in an amount effective for relieving discomfort on a stump of an amputated limb and wherein said packaging material comprises a notice which indicates that said hyaluronic acid salt can be used for relieving such discomfort.
- the subject invention also provides an article of manufacture comprising packaging material and a hyaluronic acid salt contained within said packaging material, wherein said hyaluronic acid salt is present in an amount effective for relieving discomfort caused by chafed skin and wherein said packaging material comprises a notice which indicates that said hyaluronic acid salt can be used for relieving discomfort caused by chafing of the skin.
- the skin lesions were apparently the result of the abrasive effect of the prosthesis on the stump and/or friction between the prosthesis and the stump and/or chafing, pressure and perspiration (sweating) .
- the skin lesions consisted of painful, red, infected wounds lacking skin. As a result of the wounds, the subject could not wear his prosthesis.
- AMPU-BALMTM contains benzoin, methyl salicylate, phenol (0.30%) and Mutton-Tallow (Southern Prosthetic Supply Co.) , and it healed the wounds at a very slow rate, while the subject continued to have discomfort. Thus, the success of AMPU-BALMTM was limited.
- the subject was then provided with a solution of NaHA, produced essentially as described for "cosmetic grade" sodium hyaluronate in coassigned U.S. Patent Nos. 4,780,414 and 4, 784, 990.
- the NaHA solution consisted of:
- Germall and Phenonip are preservatives; Germall is commercial preparation of imidazolidinylurea and Phenonip is a mixture of various parabens (methyl, propyl, etc.)
- the soldiers were provided with a solution of NaHA as described above in Example 1.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Prostheses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
The subject invention provides a method of relieving and preventing discomfort experienced by an amputee upon wearing a prosthetic device on a stump of an amputated limb and a method of relieving and preventing discomfort associated with chafing of the skin.
Description
METHOD FOR RELIEVING OR TREATING SKIN DISCOMFORT
This application is a continuation-in-part of U.S. Serial No. 08/386,100, filed February 10, 1995.
Throughout this specification, various publications are referenced by Arabic numerals within parentheses. Full citations for these references may be found at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this specification in order to more fully describe the state of the art to which this invention pertains.
Background of the Invention
Sodium hyaluronate (NaHA) is a naturally occurring glycosaminoglycan consisting of a linear polymer of molecular weight of 50-13000 kDa and is made of repeating units of glucuronic acid and N-acetyl-glucosamine, bound by alternating 1-3 and 1-4 bonds.
NaHA is present in various connective tissues of animals, such as skin and cartilage. Some organs are specifically rich in HA, such as the umbilical cord, synovial fluid, the vitreous humor, and rooster combs. In addition, NaHA is produced by various microorganisms, such as Streptococci Type A and C.
In skin and cartilage, the role of NaHA is to bind water and retain the tonicity and elasticity of the tissue. In joint fluids, the viscous NaHA solution serves as a lubricant to provide a protective environment to the cells.
In man and other animals, it is known that synovial fluid acts to lubricate effectively the surfaces of bones that are in frictional contact to form joints (3) . Generally, NaHA
is used by means of interarticular injections, as adjuvant in the therapy of degenerative and/or inflammatory diseases of the articular synovial sheaths (2) .
NaHA is widely used in ophthalmic surgery, due to its elasto-viscous properties and rheologic properties (1) . Particularly, NaHA is used in cataract operations that are associated with intraocular lens implantation, as well as glaucoma and corneal transplant operations and more generally in any traumatopathy involving retinal detachment (2) .
Moreover, diluted solutions of NaHA, less than 0.2%w/v, may be used to relieve symptoms of lacrimal film diseases (2) .
People with amputated limbs who wear prostheses may suffer from skin lesions on the stump of the amputated limb as a result of the pressure and the abrasive effect of the prosthesis on the stump of the amputated limb; such lesions encompass infections and inflammations of the skin.
The instant invention relates to a method of relieving and preventing discomfort experienced by an amputee upon wearing a prosthetic device on a stump of an amputated limb.
In addition, the instant invention relates to method of relieving and preventing discomfort associated with chafing of skin.
Summary of the Invention
The subject invention provides a method of relieving and preventing discomfort experienced by an amputee upon wearing a prosthetic device on a stump of an amputated limb while permitting continued wearing by the amputee of the prosthetic device which comprises applying to the surface of the stump an amount of a hyaluronic acid salt effective to relieve such discomfort prior to placing the prosthetic device on the stump and then placing the prosthetic device on the stump without removing the hyaluronic acid salt.
The subject invention further provides a method of relieving and preventing discomfort associated with chafing of skin which comprises applying to the surface of the chafed skin an amount of a hyaluronic acid salt effective to relieve such discomfort .
Detailed Description of the Invention
The term "hyaluronic acid salt" as used herein encompasses hyaluronic acid or any of its salts.
The sodium salt of hyaluronic acid is especially preferred but other salts are also envisaged, see e.g. coassigned U.S. Patent No. 4,784,991.
The hyaluronic acid salt may be produced from any source including bacteria, cockscombs or umbilical cord and may be produced by any purification procedure known in the art.
The preferred hyaluronic acid salt was produced essentially as described in coassigned U.S. Patent Nos . 4,780,414 and 4,784,990. NaHA may also be produced as described in U.S. Patent No. 4,141,973 (Balazs) or EPO Patent Publication No. 144019 (Brown et al. ) .
The subject invention provides a method of relieving and preventing discomfort experienced by an amputee upon wearing a prosthetic device (artificial limb) on a stump of an amputated limb while permitting continued wearing by the amputee of the prosthetic device which comprises applying to the surface of the stump an amount of a hyaluronic acid salt effective to relieve such discomfort prior to placing the prosthetic device on the stump and then placing the prosthetic device on the stump without removing the hyaluronic acid salt.
In a preferred embodiment there is a skin lesion on the stump.
The term "skin lesion" as used herein encompasses skin redness or soreness, painful tissue, dermatologically irritated skin, blisters and open wounds.
In a more preferred embodiment, the skin lesion is a skin wound and the hyaluronic acid salt is sodium hyaluronate.
It is envisaged that hyaluronic acid salts may be used to treat skin lesions on the stump of an amputated limb.
It is also envisaged that hyaluronic acid salts may be used prophylactically to prevent the formation of skin lesions on the stump of an amputated limb.
The subject invention further provides a method of relieving and preventing discomfort associated with chafing of the skin which comprises applying to the surface of the chafed skin an amount of a hyaluronic acid salt effective to relieve such discomfort.
In a preferred embodiment the chafed skin comprises a chafed upper leg and the hyaluronic acid salt is sodium hyaluronate.
The subject invention also provides a use of an effective amount of a hyaluronic acid salt in the preparation of a composition for relieving and preventing discomfort experienced by an amputee upon wearing a prosthetic device on a stump of an amputated limb while permitting continued wearing by the amputee of the prosthetic device which comprises applying to the surface of the stump an amount of the composition effective to relieve and prevent such discomfort prior to placing the prosthetic device on the stump, and then placing the prosthetic device on the stump without removing the composition.
The subject invention additionally provides a use of an effective amount of a hyaluronic acid salt in the preparation of a composition for relieving and preventing discomfort associated with chafing of skin which comprises applying to the surface of the chafed skin an amount of the
composition effective to relieve and prevent such discomfort.
The hyaluronic acid salt may be chemically modified or cross-linked in any manner, see for example U.S. 4,957,744 or U.S. 4,713,448, as long as the product is effective in the claimed use and can be used to relieve discomfort.
The hyaluronic acid salt solution of the subject invention may have a concentration of from 0.05% to 5 % and preferably from 0.1% to 2%. The most preferred concentration of the hyaluronic acid salt solution to be used is from 0.1% to 1%.
The molecular weight of the hyaluronic acid salt to be utilized may be from 30,000 to 13 million daltons and preferably from 300,000 to 2,000,000 daltons. Hyaluronic acid salts of various molecular weights are well known in the art; see for example EP Patent Publication
197718. The most preferred hyaluronic acid salt has a molecular weight of from 500,000 to 1,500,000 daltons.
The hyaluronic acid salt solution may be administered with or without preservatives; any suitable preservative known in the art may be used.
In the best embodiment, the hyaluronic acid salt solution has a concentration of about 0.5%, a molecular weight of between 700,000 to 1,500,000 daltons and comprises Germall and Phenonip preservatives.
The subject invention further provides an article of manufacture comprising packaging material and a hyaluronic acid salt contained within said packaging material, wherein said hyaluronic acid salt is present in an amount effective for relieving discomfort on a stump of an amputated limb and wherein said packaging material comprises a notice which indicates that said hyaluronic acid salt can be used for
relieving such discomfort.
The subject invention also provides an article of manufacture comprising packaging material and a hyaluronic acid salt contained within said packaging material, wherein said hyaluronic acid salt is present in an amount effective for relieving discomfort caused by chafed skin and wherein said packaging material comprises a notice which indicates that said hyaluronic acid salt can be used for relieving discomfort caused by chafing of the skin.
EXAMPLE 1
A 63 year old subject, who wears a prosthesis due to an amputated leg above the knee, suffered from skin lesions on the stump of the amputated leg. The skin lesions were apparently the result of the abrasive effect of the prosthesis on the stump and/or friction between the prosthesis and the stump and/or chafing, pressure and perspiration (sweating) . The skin lesions consisted of painful, red, infected wounds lacking skin. As a result of the wounds, the subject could not wear his prosthesis.
The subject originally applied AMPU-BALM™ to the stump. AMPU-BALM™ contains benzoin, methyl salicylate, phenol (0.30%) and Mutton-Tallow (Southern Prosthetic Supply Co.) , and it healed the wounds at a very slow rate, while the subject continued to have discomfort. Thus, the success of AMPU-BALM™ was limited.
The subject was then provided with a solution of NaHA, produced essentially as described for "cosmetic grade" sodium hyaluronate in coassigned U.S. Patent Nos. 4,780,414 and 4, 784, 990.
The NaHA solution consisted of:
NaHA 5 g
Germall 2 g
Phenonip 3 g
Deionized water 1 L
Germall and Phenonip are preservatives; Germall is commercial preparation of imidazolidinylurea and Phenonip is a mixture of various parabens (methyl, propyl, etc.)
When the subject rubbed the solution provided on the wounds on the stump at least once in 24 hours, scar tissue formed over the wounds within those 24 hours and the subject could again wear his prosthesis without discomfort. When the subject continued rubbing NaHA on the wounds, they healed completely and at a much faster rate than when using AMPU- BALM™ and the subject had much more relief of discomfort.
Unfortunately, after a few months the subject's supply of NaHA was exhausted and he was compelled to use AMPU-BALM™. The subject then once again suffered from discomfort due to lesions .
Several months later, the subject was again supplied with a solution of NaHA as described above but he did not apply it to the stump. Shortly afterwards, superficial wounds developed on the stump. The subject immediately applied the NaHA solution to the wounds on the stump twice every 24 hours for two days while continuing to wear his prosthesis. The wounds healed within two days.
EXAMPLE 2
Three soldiers (aged 18-21, in the Israel Defense Force) suffered from chafing on their upper legs (in the groin) . The chafing was apparently the result of friction on the upper legs which occurred during long marches carried out by the soldiers in the course of their duties.
The soldiers were provided with a solution of NaHA as described above in Example 1.
When the soldiers rubbed the solution provided on the chafed legs three times daily, the solution relieved the discomfort due to the chafing and the chafed areas healed within 24 hours.
It is intended that the foregoing descriptions are by way of illustration only and are not to be construed as limiting the invention in any way except in the spirit and scope of the appended claims.
References
1. Balazs, E.A., Fed. Proc. 17: 1086-1093, 1958.
2. EPO Publication No. EP 553593.
3. PCT International Publication No. WO 89/01777.
Claims
1. A method of relieving discomfort experienced by an amputee upon wearing a prosthetic device on a stump of an amputated limb while permitting continued wearing by the amputee of the prosthetic device which comprises applying to the surface of the stump an amount of a hyaluronic acid salt effective to relieve such discomfort prior to placing the prosthetic device on the stump, and then placing the prosthetic device on the stump without removing the hyaluronic acid salt .
2. The method according to claim 1, wherein there is a skin lesion on the stump.
3. The method according to claim 2, wherein the skin lesion is a skin wound.
4. The method according to claim 1, wherein the hyaluronic acid salt is sodium hyaluronate.
5. A method of relieving discomfort associated with chafing of skin which comprises applying to the surface of the chafed skin an amount of a hyaluronic acid salt effective to relieve such discomfort.
6. The method according to claim 5, wherein the chafed skin comprises a chafed upper leg.
7. The method according to claim 5, wherein the hyaluronic acid salt is sodium hyaluronate.
8. An article of manufacture comprising packaging material and a hyaluronic acid salt contained within said packaging material, wherein said hyaluronic acid salt is present in an amount effective for relieving discomfort on a stump of an amputated limb and wherein said packaging material comprises a notice which indicates that said hyaluronic acid salt can be used for relieving such discomfort.
An article of manufacture comprising packaging material and a hyaluronic acid salt contained within said packaging material, wherein said hyaluronic acid salt is present in an amount effective for relieving discomfort caused by chafed skin and wherein said packaging material comprises a notice which indicates that said hyaluronic acid salt can be used for relieving discomfort caused by chafing of the skin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU49174/96A AU4917496A (en) | 1995-02-10 | 1996-02-07 | Method for relieving or treating skin discomfort |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38610095A | 1995-02-10 | 1995-02-10 | |
| US08/386,100 | 1995-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1996024361A1 true WO1996024361A1 (en) | 1996-08-15 |
Family
ID=23524155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/001669 Ceased WO1996024361A1 (en) | 1995-02-10 | 1996-02-07 | Method for relieving or treating skin discomfort |
Country Status (4)
| Country | Link |
|---|---|
| AU (1) | AU4917496A (en) |
| IL (1) | IL116754A0 (en) |
| WO (1) | WO1996024361A1 (en) |
| ZA (1) | ZA961058B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4784991A (en) * | 1986-03-14 | 1988-11-15 | Bio-Technology General Corp. | Heavy metal salts of hyaluronic acid and their use as antimicrobial agents |
| US5166331A (en) * | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| EP0552593A1 (en) * | 1992-01-20 | 1993-07-28 | SOCIETA'INDUSTRIA FRAMACEUTICA ITALIANA S.p.A. | Use of hyaluronic acid as ocular prosthesis lubricant |
| GB2280372A (en) * | 1993-07-28 | 1995-02-01 | Johnson & Johnson Medical | Composite surgical material |
-
1996
- 1996-01-14 IL IL11675496A patent/IL116754A0/en unknown
- 1996-02-07 WO PCT/US1996/001669 patent/WO1996024361A1/en not_active Ceased
- 1996-02-07 AU AU49174/96A patent/AU4917496A/en not_active Abandoned
- 1996-02-09 ZA ZA961058A patent/ZA961058B/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166331A (en) * | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| US4784991A (en) * | 1986-03-14 | 1988-11-15 | Bio-Technology General Corp. | Heavy metal salts of hyaluronic acid and their use as antimicrobial agents |
| EP0552593A1 (en) * | 1992-01-20 | 1993-07-28 | SOCIETA'INDUSTRIA FRAMACEUTICA ITALIANA S.p.A. | Use of hyaluronic acid as ocular prosthesis lubricant |
| GB2280372A (en) * | 1993-07-28 | 1995-02-01 | Johnson & Johnson Medical | Composite surgical material |
Also Published As
| Publication number | Publication date |
|---|---|
| IL116754A0 (en) | 1996-05-14 |
| ZA961058B (en) | 1996-08-29 |
| AU4917496A (en) | 1996-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huynh et al. | Hyaluronic acid applications in ophthalmology, rheumatology, and dermatology | |
| US4983585A (en) | Viscoelastic fluid for use in surgery and other therapies and method of using same | |
| Van Valburg et al. | Joint distraction in treatment of osteoarthritis: a two-year follow-up of the ankle | |
| US5156839A (en) | Viscoelastic fluid for use in spine and general surgery and other surgery and therapies and method of using same | |
| CA2266811C (en) | Method and composition for wound treatment | |
| EP0167363B1 (en) | Crosslinked glycosaminoglycans and their use | |
| US4486416A (en) | Protection of human and animal cells subject to exposure to trauma | |
| US5492936A (en) | Bimodal molecular weight hyaluronate formulations and methods for using same | |
| Balazs | Hyaluronan as an ophthalmic viscoelastic device | |
| JP7074951B2 (en) | Silicone oil-in-water composition useful as an injectable filler and as a scaffold for collagen growth | |
| JP5646446B2 (en) | Use of biocompatible polymers to make medical compounds or products | |
| JPH11500032A (en) | Biodegradable eye shield | |
| US20240358743A1 (en) | Cosmetic/dermatological composition | |
| JP2009515921A (en) | Pharmaceutical composition free of dexpantenol, calcium ions and phosphate, and the use of calcium chelators and ophthalmically compatible viscosity modifiers | |
| EP1814518A1 (en) | Triple natural polymer viscoelastic composition | |
| US11376276B2 (en) | Lubricating block copolymers and their use as biomimetic boundary lubricants | |
| EP0875248B1 (en) | Use of hyaluronic acid for the preparation of an aqueous solution useful as intra-articular lavage liquid | |
| WO1989000044A1 (en) | Artificial lacrima | |
| JPH08503701A (en) | Ophthalmic solutions and methods of use | |
| EP1793836A2 (en) | Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same | |
| WO1996024361A1 (en) | Method for relieving or treating skin discomfort | |
| EP0359766A4 (en) | Improved viscoelastic fluid for ophthalmic surgery and method of using same | |
| AU2002356300B2 (en) | Cosmetic scar management composition | |
| EP0477833A1 (en) | Composition for therapeutic and/or cosmetic use for treatment of circulatory diseases and for aesthetic medicine treatments | |
| EP0552593A1 (en) | Use of hyaluronic acid as ocular prosthesis lubricant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase |